Maastricht, The Netherlands, 28 November 2017 – Cristal Therapeutics, a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, today announced that it secured a €2.5 million grant from the European Commission’s Horizon 2020 programme. The funds will be used to perform the upcoming […]
Maastricht, The Netherlands, 1 November 2017 – Cristal Therapeutics, a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, announced today that it has begun a Phase 1b clinical program of its lead nanomedicine candidate CriPec®-docetaxel in patients with solid tumours. This CriPec®-docetaxel program will […]
Maastricht, The Netherlands, 24 October 2017 – Cristal Therapeutics, a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, has appointed Dr. Istvan Udvaros as its Chief Medical Officer (CMO) with immediate effect. He will be responsible for the clinical strategy and development of […]
Cristal Therapeutics Further Strengthens its Scientific Advisory Board with Appointment of Dr Paul Lammers Maastricht, The Netherlands, August 9, 2017 – Cristal Therapeutics, a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, today announced the appointment of Dr Paul Lammers to its Scientific […]
Cristal Therapeutics raises €12.8 million in new financing round to advance novel medicines against cancer using its CriPec® nanotech platform Round led by Aglaia BioMedical Ventures and DROIA Oncology Ventures Funding used: to execute clinical phase Ib and phase IIa trials with CriPec® docetaxel to further leverage the CriPec® platform for oligonucleotides programs from proof […]
© Cristal Therapeutics
Oxfordlaan 55
6229 EV Maastricht
Netherlands
